Richard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock

Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $19.35, for a total value of $580,500.00. Following the completion of the sale, the director now owns 286,975 shares in the company, valued at approximately $5,552,966.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard Aldrich also recently made the following trade(s):

  • On Thursday, February 1st, Richard Aldrich sold 11,946 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.89, for a total value of $249,551.94.
  • On Friday, January 26th, Richard Aldrich sold 5,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.46, for a total value of $102,300.00.
  • On Monday, January 29th, Richard Aldrich sold 18,054 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.63, for a total value of $372,454.02.
  • On Monday, January 22nd, Richard Aldrich sold 10,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.55, for a total value of $195,500.00.
  • On Wednesday, January 24th, Richard Aldrich sold 30,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.68, for a total value of $590,400.00.
  • On Tuesday, January 16th, Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock. The stock was sold at an average price of $19.14, for a total value of $597,857.04.

Shares of Concert Pharmaceuticals Inc (NASDAQ CNCE) traded down $0.13 during trading hours on Friday, hitting $20.09. The stock had a trading volume of 335,330 shares, compared to its average volume of 628,774. Concert Pharmaceuticals Inc has a 52-week low of $8.84 and a 52-week high of $30.71. The stock has a market cap of $457.51, a price-to-earnings ratio of 5.40 and a beta of 1.23.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. equities analysts expect that Concert Pharmaceuticals Inc will post 4.1 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in Concert Pharmaceuticals in the 3rd quarter valued at $153,000. Alliancebernstein L.P. acquired a new position in Concert Pharmaceuticals in the 2nd quarter valued at $174,000. Princeton Capital Management Inc. acquired a new position in Concert Pharmaceuticals in the 3rd quarter valued at $215,000. The Manufacturers Life Insurance Company increased its stake in shares of Concert Pharmaceuticals by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 287 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Concert Pharmaceuticals by 213.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 15,650 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 10,650 shares during the last quarter. 67.20% of the stock is owned by hedge funds and other institutional investors.

CNCE has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Concert Pharmaceuticals in a research report on Friday, October 20th. Stifel Nicolaus restated a “buy” rating and issued a $30.00 price objective on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. Zacks Investment Research lowered Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Mizuho initiated coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, TheStreet upgraded Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Concert Pharmaceuticals has an average rating of “Buy” and a consensus target price of $24.33.

TRADEMARK VIOLATION WARNING: “Richard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/02/12/concert-pharmaceuticals-inc-cnce-director-richard-aldrich-sells-30000-shares.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply